ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026
Deep learning-based MRI analysis reveals Lewy body co-pathology accelerates brain aging in Alzheimer's disease.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
7 authors.
Funding
Abstract
introductionLewy body (LB) co-pathology is common in Alzheimer's disease (AD), yet its in vivo impact on neurodegeneration remains unclear.
methodsWe trained a 3D-DenseNet on multi-cohort T1-weighted magnetic resonance imaging (MRI) from cognitively unimpaired individuals to estimate brain age (BA) and applied it to cognitively impaired Alzheimer's Disease Neuroimaging Initiative (ADNI) participants stratified by cerebrospinal fluid (CSF) p-tau
resultsThe model robustly captured normative aging. AD+LB+ exhibited the greatest and fastest-increasing BAG, with saliency maps emphasizing regions that also showed steeper longitudinal atrophy and concordant cognitive decline, and BAG mediated a substantial portion of LB-related cognitive impairment within AD+. DISCUSSION: LB co-pathology confers an additional neurodegenerative burden in AD, underscoring the importance of combined biomarker assessment and targeted interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.